

# Equatorial Guinea

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.063 (0.04–0.092)	7.5 (4.8–11)
Mortality (HIV+TB only)	0.12 (0.032–0.27)	14 (3.8–32)
Incidence (includes HIV+TB)	1.5 (1.3–1.6)	172 (150–194)
Incidence (HIV+TB only)	0.73 (0.62–0.84)	86 (74–99)
Incidence (MDR/RR-TB)**	0.066 (<0.01–0.12)	7.8 (1–14)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.099 (0.073–0.13)	0.56 (0.43–0.69)	0.66 (0.5–0.82)
Males	0.066 (0.047–0.085)	0.72 (0.57–0.88)	0.79 (0.62–0.96)
Total	0.17 (0.13–0.2)	1.3 (1.2–1.4)	1.5 (1.3–1.6)

TB case notifications, 2015	
Total cases notified	1 286
Total new and relapse	1 242
- % tested with rapid diagnostics at time of diagnosis	17%
- % with known HIV status	73%
- % pulmonary	91%
- % bacteriologically confirmed among pulmonary	72%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	86% (76–98)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.13 (0.06–0.23)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	452	50%
- on antiretroviral therapy	294	65%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			55 (8–100)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	21% (2.2–39)	
% notified tested for rifampicin resistance	11%	32%	164
MDR/RR-TB cases tested for resistance to second-line drugs			18
Laboratory-confirmed cases		MDR/RR-TB: 39, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 26, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	58%	551
Previously treated cases, excluding relapse, registered in 2014	14%	78
HIV-positive TB cases, all types, registered in 2014	28%	287
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	2%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed



## Tuberculosis profile



Mortality (excludes HIV+TB)



Incidence  
Notified (new and relapse)  
Incidence (HIV+TB only)



New and relapse  
Retreatment, excluding relapse  
HIV-positive MDR/RR-TB XDR-TB

